Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Ambrx, a US-China Biotech, Raises $45 Million for Clinical Trials

publication date: Aug 5, 2016
Ambrx, a San Diego biopharma, closed a $45 million financing round that will be used for a Phase I trial of its lead candidate, ARX788, a treatment for HER2-positive breast cancer. Last year, Ambrx was acquired by a consortium of China pharmas and investment firms, including Fosun Pharma and WuXi AppTec, for an undisclosed price. The latest fundraising was led by US investors Apricot Capital and Northeast Securities Prosperity Healthcare Fund. It was joined by an all-China group including new investors Sinopharm Capital and Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments and Everbright Limited Healthcare. More details....

Stock Symbol: (SHA: 600196; HK: 02196)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital